Valeant Pharmaceutical (VRX) Reports Q2 Earnings of $0.73; Raises FY11 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Shares used in per share computation - Basic: 77.14M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Shares used in per share computation - Basic: 77.14M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q2 EPS of $0.73, versus $0.60 reported last year. Revenue for the quarter came in at $609 million versus the consensus estimate of $297.08 million.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.
Valeant Pharmaceuticals International, Inc. sees FY2011 EPS of $2.70-$3.00, versus prior guidance of $2.65-$2.90.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AI chip sell-off is ‘unmoored from fundamentals,’ LYNX says
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
